The Billionaires Spending a Fortune to Lure Scientists Away From Universities

user avatar Author: Editors Desk Source: N.Y Times
January 12, 2024 at 06:14
Bob O'Connor for The New York Times
Bob O'Connor for The New York Times

Arena BioWorks is promising big paydays to nearly 100 researchers from Harvard, M.I.T. and other prestigious institutions.


By Rob Copeland
To report this article, Rob Copeland, a finance reporter, spoke to a host of wealthy financiers and acclaimed scientists, as well as toured an unmarked laboratory in Cambridge, Mass.

In an unmarked laboratory stationed between the campuses of Harvard and the Massachusetts Institute of Technology, a splinter group of scientists is hunting for the next billion-dollar drug.

The group, bankrolled with $500 million from some of the wealthiest families in American business, has created a stir in the world of academia by dangling seven-figure paydays to lure highly credentialed university professors to a for-profit bounty hunt. Its self-described goal: to avoid the blockages and paperwork that slow down the traditional paths of scientific research at universities and pharmaceutical companies, and discover scores of new drugs (at first, for cancer and brain disease) that can be produced and sold quickly.

Braggadocio from start-ups is de rigueur, and plenty of ex-academics have started biotechnology companies, hoping to strike it rich on their one big discovery. This group, rather boastfully named Arena BioWorks, borrowing from a Teddy Roosevelt quote, doesn’t have one singular idea, but it does have a big checkbook.

“I’m not apologetic about being a capitalist, and that motivation from a team is not a bad thing,” said the technology magnate Michael Dell, one of the group’s big-money backers. Others include an heiress to the Subway sandwich fortune and an owner of the Boston Celtics.

The wrinkle is that for decades, many drug discoveries have not just originated at colleges and universities, but also produced profits that helped fill their endowment coffers. The University of Pennsylvania, for one, has said it earned hundreds of millions of dollars for research into mRNA vaccines used against Covid-19.

Under this model, any such windfall would remain private.


Michael Dell, seated in a suit, is posing for a portrait.

“I’m not apologetic about being a capitalist,” said Michael Dell, the founder and chief executive of Dell Technologies.

Credit...Guerin Blask for The New York Times

Arena has been operating in stealth mode since early fall, before the turmoil over Israel and Gaza erupted at the colleges it borders. Yet the impulse behind it, say researchers who have jumped to the new lab, is becoming only more acute as the reputations of institutions of higher learning take a hit. They say they are frustrated with the slow pace and administrative bogdowns at their former employers, as well as what one new hire, J. Keith Joung, said was “atrocious” pay at Massachusetts General Hospital, where he worked before Arena.

Arena BioWorks is housed in a mostly glass building.
Arena BioWorks, in Cambridge, Mass., borrows its name from a Teddy Roosevelt quote.Credit...Bob O'Connor for The New York Times

“It used to be that it was considered a failure to go from academia to industry,” said Dr. Joung, a pathologist who helped design the gene-editing tool CRISPR. “Now the model has flipped.”

The motivation behind Arena has scientific, financial and even emotional components. Its earliest backers first mused about the idea at a late-2021 confab at a mansion in Austin, Texas, where Mr. Dell, along with the early Facebook investor James W. Breyer and an owner of the Celtics, Stephen Pagliuca, vented to one another about the seemingly endless requests for money from collegiate fund-raisers.

Mr. Pagliuca had donated hundreds of millions of dollars to his alma maters, Duke University and Harvard, largely earmarked for science. That earned him seats on four advisory boards at the institutions, but it began to dawn on him that he didn’t have any concrete idea what all that money had produced, save for his name on a few plaques outside various university buildings.



Over the subsequent months, those early backers teamed up with a Boston venture capitalist and trained medical doctor, Thomas Cahill, to devise a plan. Dr. Cahill said he would help find frustrated academics willing to give up their hard-fought university tenure, as well as scientists from companies like Pfizer, in exchange for a hefty cut of the profits from any drugs they discovered. Arena’s billionaire backers will keep 30 percent, with the remainder flowing to scientists and for overhead.

For-profit science is, of course, nothing new; the $1.5 trillion pharmaceutical industry provides ample proof. Businessmen such as Jeff Bezos and Peter Thiel have poured hundreds of millions of dollars into start-ups that try to extend human life, and plenty of pharmaceutical companies have raided universities for talent.

A sizable percentage of drugs originate from government or university grants, or a mix of the two. From 2010 to 2016, each of the 210 new drugs approved by the Food and Drug Administration was connected to research funded by the National Institutes of Health, according to the scientific journal PNASA 2019 study from a former dean of Harvard Medical School, Jeffrey Flier, said a majority of “new insights” into biology and disease came from academia.

The inside of Arena BioWorks has white tables and chairs.
Arena’s billionaire backers will keep 20 percent, with the remainder flowing to scientists and for overhead.Credit...Bob O'Connor for The New York Times


That system has longstanding advantages. Universities, generally helped by their nonprofit status, have a nearly limitless, low-paid supply of research assistants to help scientists with early-stage research. Groundbreaking drugs, including penicillin, were born from this model.

The problem, scientists and researchers say, is that there can be yearslong waits for university institutional approvals to move forward with promising research. The process, aimed at sifting out unrealistic proposals and protecting safety, can involve writing long essays that can consume more than half of some scientists’ time. When funding does come through, the initial research idea is often already stale, setting off a new cycle of grant applications for projects sure to be outdated in their own time.

Stuart Schreiber, a longtime Harvard-affiliated researcher who quit to be Arena’s lead scientist, said his more out-there ideas rarely received backing. “It got to the point where I realized the only way to get funding was to apply to study something that had already been done,” Dr. Schreiber said.

You did not use the site, Click here to remain logged. Timeout: 60 second